GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

NKTR · Mar 31, 2025

NEKTAR THERAPEUTICS. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0000950170-25-067279General Corporate

Capex intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

0.02% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-468.96% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

-51.66% · CORE · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

100.00% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-425.76% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

291.40% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

37.27% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History12 statesHistory building

Sep 30, 20230/7 normalizedLevel 3 Dec 31, 20230/7 normalizedLevel 3 Mar 31, 20240/7 normalizedLevel 3 Jun 30, 20240/7 normalizedLevel 3 Sep 30, 20240/8 normalizedLevel 3 Dec 31, 20240/8 normalizedLevel 3 Mar 31, 20250/7 normalizedLevel 3 Jun 30, 20250/7 normalizedLevel 3 Sep 30, 20256/7 normalizedLevel 3 Dec 31, 20256/8 normalizedLevel 3 Mar 31, 20265/6 normalizedLevel 3 Jun 30, 20265/6 normalizedLevel 3

Period transition

What moved in the state?

Capex Intensity Decreased

Previous: 1.49%
Current: 0.02%
Delta: -1.47%

Cash Generation Decreased

Previous: -178.52%
Current: -468.96%
Delta: -290.44%

Growth Decreased

Previous: 9.22%
Current: -51.66%
Delta: -60.88%

Margin Increased

Previous: 68.82%
Current: 100.00%
Delta: 31.18%

Profitability Decreased

Previous: -106.88%
Current: -425.76%
Delta: -318.89%

R And D Intensity Increased

Previous: 122.84%
Current: 291.40%
Delta: 168.56%

Sbc Intensity Increased

Previous: 21.96%
Current: 37.27%
Delta: 15.31%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · NKTR Fundamental State →Has State · NEKTAR THERAPEUTICS →Transitioned To · NKTR PROFITABILITY_DECREASED →Transitioned To · NKTR R_AND_D_INTENSITY_INCREASED →Transitioned To · NKTR Fundamental State →Transitioned To · NKTR CAPEX_INTENSITY_DECREASED →Transitioned To · NKTR CASH_GENERATION_DECREASED →Transitioned To · NKTR GROWTH_DECREASED →Transitioned To · NKTR MARGIN_INCREASED →Transitioned To · NKTR SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.